tcf-no-longer-accepting-cases

September 29, 2014 — Bayer HealthCare has been hit with a lawsuit from a woman who used Avelox, a popular antibiotic, and developed peripheral neuropathy (nerve damage).

According to the complaint:

“Rather than warning patients and physician that the use of Avelox may result in permanent nerve damage, Defendants instead adopted a warning that misleadingly indicated such damage was rare and failed to make any mention of the risk of permanent nerve damage.”

Evidence linking fluoroquinolone antibiotics and peripheral neuropathy has been growing since the early 1990s. One study published in 2001 described dozens of cases that occurred rapidly (within days of taking the first dose) and caused persistent complications.

However, the U.S. Food and Drug Administration (FDA) did not require warnings about the side effect until 2004. Drug-makers warned about “rare cases” of sensory nerve damage, resulting in paresthesia (tingling, burning, pricking, etc.), loss of sensation, weakness, and other abnormal sensations.

In 2013, the FDA published an updated warning to emphasize the rapid onset of nerve damage and permanent complications.

Lawsuits allege that drug-makers knew or should have known about these risks, but failed to adequately warn doctors and patients. In August, a study published in Neurology found that fluoroquinolone antibiotics could double a patient’s risk of peripheral neuropathy.

 

Meet Your Attorney

Collen A. Clark

Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.

“Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”

To contact Collen, please fill out the contact form below:

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 879-3040.
  • This field is for validation purposes and should be left unchanged.